Antiplatelet Therapy: Improving the Care of ACS Patients through Evidence-Based Approaches
Organized by the Sahlgrenska Academy, University of Gothenburg, Sweden
Course Director: Professor Karl Swedberg
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for "1" hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Distance Learning CME Program
Duration Speaker / Country
Introduction & welcome
1.32 min
Philippe Gabriel Steg / France
Improving Care with Oral Antiplatelet Therapy:Lessons from Recent Large Outcomes Trials.
15.58 min Philippe Gabriel Steg / France
New Mechanisms, New Agents in Antiplatelet Therapy
13.59 min Marco Catteneo / Italy
Biomarkers in ACS: Prognostic Indicators or Meaningful Endpoints
14.32 min Rob Storey / United Kingdom
Genetic Influences on Platelet Function: Recent Insights
15.13 min Paul Gurbel / USA
Panel and general discussion
20.18 min Chairman and faculty
In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities
Supported by an unrestricted educational grant from AstraZeneca
Determination of educational needs:
Determined by the Chairman and the faculty of the scientific session.
Oral antiplatelet therapy is a cornerstone of antithrombotic treatment in patients with acute coronary syndromes.(ACS). However, traditional therapy with clopidogrel has several limitations, including variable inter-individual platelet effects and low inhibition of platelet aggregation. Optimal care of ACS patients requires that clinicians recognize the challenges involved in balancing the benefits and risks associated with current treatments, as well as understand the potential improvements in patient care that emerging therapeutic approaches may provide.
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
Powered by MULTIWEBCAST Technologies. MULTIWEBCAST PLATFORM Version 4.1000. All rights reserved.
